Literature DB >> 20852827

The melanocortin system in control of inflammation.

Anna Catania1, Caterina Lonati, Andrea Sordi, Andrea Carlin, Patrizia Leonardi, Stefano Gatti.   

Abstract

Melanocortin peptides, the collective term for alpha-, beta-, and gamma-melanocyte-stimulating hormone (alpha-, beta-, gamma-MSH) and adrenocorticotropic hormone (ACTH), are elements of an ancient modulatory system. Natural melanocortins derive from the common precursor pro-opiomelanocortin (POMC). Five receptor subtypes for melanocortins (MC1-MC5) are widely distributed in brain regions and in peripheral cells. Melanocortin receptor activation by natural or synthetic ligands exerts marked anti-inflammatory and immunomodulatory effects. The anticytokine action and the inhibitory influences on inflammatory cell migration make melanocortins potential new drugs for treatment of inflammatory disorders. Effectiveness in treatment of acute, chronic, and systemic inflammatory disorders is well documented in preclinical studies. Further, melanocortins are promising compounds in neuroprotection. This review examines the main signaling circuits in anti-inflammatory and immunomodulatory actions of melanocortins, and the potential therapeutic use of these molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852827      PMCID: PMC5763663          DOI: 10.1100/tsw.2010.173

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  56 in total

1.  Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.

Authors:  Jodi F Evans; Anne Fernando; Louis Ragolia
Journal:  Mol Cell Endocrinol       Date:  2012-01-27       Impact factor: 4.102

2.  Viability selection affects black but not yellow plumage colour in greenfinches.

Authors:  Peeter Hõrak; Marju Männiste
Journal:  Oecologia       Date:  2015-09-19       Impact factor: 3.225

Review 3.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 4.  Intracellular signaling mechanisms of the melanocortin receptors: current state of the art.

Authors:  Adriana R Rodrigues; Henrique Almeida; Alexandra M Gouveia
Journal:  Cell Mol Life Sci       Date:  2014-12-12       Impact factor: 9.261

Review 5.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 6.  Control of myeloid cell trafficking in resolution.

Authors:  Lucy V Norling; Mauro Perretti
Journal:  J Innate Immun       Date:  2013-04-30       Impact factor: 7.349

7.  Biphasic effect of melanocortin agonists on metabolic rate and body temperature.

Authors:  Beth Lute; William Jou; Dalya M Lateef; Margalit Goldgof; Cuiying Xiao; Ramón A Piñol; Alexxai V Kravitz; Nicole R Miller; Yuning George Huang; Clemence Girardet; Andrew A Butler; Oksana Gavrilova; Marc L Reitman
Journal:  Cell Metab       Date:  2014-06-26       Impact factor: 27.287

8.  Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.

Authors:  Jodi F Evans; Louis Ragolia
Journal:  Med Hypotheses       Date:  2012-09-29       Impact factor: 1.538

Review 9.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

Review 10.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.